IRVINE, Calif., April 16, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today details for its previously announced conference call and webcast to discuss the United States Food and Drug Administration (FDA) 510(k) clearance of the UltraShape System for selective non-invasive fat cell destruction for the purpose of body contouring.
The conference call and webcast will be hosted by Syneron management and will take place at 8:30 am ET on Thursday, April 17, 2014. The webcast will include presentation slides regarding FDA clearance of the UltraShape System, its characteristics and its business potential to accompany management's prepared remarks. A question & answer session will follow management's prepared remarks.
Investors and analysts may participate in the conference call and question & answer session using the following dial-in numbers:
US (toll free): (877) 359-9508
International: (224) 357-2393
The conference passcode for both is 31286954.
Investors and analysts are also encouraged to access the live webcast of the conference call, which will include accompanying presentation slides.
The live webcast of the conference call can be accessed through the Investor Relations page on Syneron's website at www.investors.syneron.com. Please log-in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the conference call, a replay of the webcast will be available within 24 hours on the Company's website.
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit www.syneron-candela.com.
SOURCE Syneron Medical Ltd.